CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

RSV

nanobio

NanoBio To Present Data On Herpes, RSV Vaccines

NanoBio Corp. announced the company will present new data at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy meeting showing the safety and effectiveness of a vaccine for the prevention of respiratory syncytial virus, enhanced by the company’s nanoemulsion technology.

WWJ Newsradio 950–09/11/2013

nanobio

Ann Arbor Firm’s Technology Makes Vaccines More Effective

NanoBio Corp. Tuesday said that it is presenting new data demonstrating positive pre-clinical results for its intramuscular respiratory syncytial virus vaccine at the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research.

WWJ Newsradio 950–04/23/2013

nanobio

NanoBio Closes $11 Million Series C Financing

NanoBio Corp. announced Wednesday the closing of an $11 million Series C financing, including full participation from its existing investor syndicate.

WWJ Newsradio 950–11/28/2012

nanobio

NanoBio To Present Data On RSV Vaccine

NanoBio Corp. said it will present data from two separate preclinical studies at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy meeting this week in San Francisco.

WWJ Newsradio 950–09/10/2012

nanobio

NanoBio In RSV Vaccine Research Effort With Merck

Nanobio Corp. Thursday announced a preclinical collaboration with a subsidiary of Merck & Co. Inc. focused on the development of a vaccine for Respiratory Syncytial Virus (RSV).

WWJ Newsradio 950–12/08/2011

nanobio

NanoBio’s Intranasal Vaccine Induces Robust Immunity in Animals

NanoBio Corp. announced Wednesday that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus vaccine have shown strong immunity effects, paving the way for more studies of the nanoparticle-based technology.

WWJ Newsradio 950–08/24/2011

nanobio

NanoBio Secures Novel Antigen Source For Intranasal RSV Vaccine

Ann Arbor-based NanoBio Corp. last week announced a licensing agreement with the National Institutes of Health that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

WWJ Newsradio 950–08/08/2011

research

NanoBio Gets $6M Gates Grant For Nasal RSV Vaccine

Ann Arbor-based NanoBio Corporation announced Tuesday that it has received a $6 million grant from the Bill & Melinda Gates Foundation to support development of an intranasal vaccine for Respiratory Syncytial Virus.

11/30/2010